Fennec Pharmaceuticals (FENC) CFO gains 1,703 additional shares

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. Chief Financial Officer Robert Andrade acquired 1,703 common shares on April 30, 2026 through an exercise or conversion of a derivative security reported at $0.00 per share.

After this transaction, Andrade directly owns 287,566 common shares. A footnote explains these shares were released from restriction from awards originally granted on May 16, 2024 and March 28, 2025.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Andrade Robert

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Exercise	Common shares	1,703	$0.00	--

Holdings After Transaction: Common shares — 287,566 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 1,703 common shares Transaction price per share: $0.00 per share Total shares after transaction: 287,566 common shares +1 more

4 metrics

Shares acquired 1,703 common shares Exercise or conversion on April 30, 2026

Transaction price per share $0.00 per share Reported for the 1,703-share acquisition

Total shares after transaction 287,566 common shares Direct holdings following April 30, 2026 transaction

Transaction code M Exercise or conversion of derivative security

Key Terms

Exercise or conversion of derivative security, Common shares, total shares following transaction, released from restriction

4 terms

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

Common shares financial

"security_title: Common shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

total shares following transaction financial

"total_shares_following_transaction: 287566.0000"

released from restriction financial

"Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrade Robert

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	04/30/2026		M		1,703	A	$0	287,566	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025.

	/s/ Robert Andrade	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Fennec Pharmaceuticals (FENC) report for its CFO?

Fennec Pharmaceuticals reported that CFO Robert Andrade acquired 1,703 common shares on April 30, 2026. The shares came from exercising or converting a derivative security, increasing his direct ownership stake reported in this Form 4 filing.

How many Fennec Pharmaceuticals (FENC) shares does the CFO hold after this Form 4?

After the reported transaction, CFO Robert Andrade directly holds 287,566 common shares of Fennec Pharmaceuticals. This total includes the 1,703 shares acquired on April 30, 2026 through exercise or conversion of a derivative security.

What does the 1,703-share transaction in Fennec (FENC) stock represent?

The 1,703-share transaction represents common shares acquired via exercise or conversion of a derivative security. A footnote states these shares were released from restriction tied to awards originally granted on May 16, 2024 and March 28, 2025.

Did the Fennec (FENC) CFO pay a purchase price for the 1,703 acquired shares?

The Form 4 reports a transaction price of $0.00 per share for the 1,703 common shares. This indicates the shares were acquired through an exercise or conversion event rather than an open-market purchase at a positive share price.

Is the Fennec Pharmaceuticals (FENC) CFO’s Form 4 transaction a buy or a sale?

The Form 4 characterizes the transaction as an acquisition through exercise or conversion of a derivative security. It is not reported as an open-market sale or purchase, but as shares added to the CFO’s direct holdings.